<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177603</url>
  </required_header>
  <id_info>
    <org_study_id>206246</org_study_id>
    <nct_id>NCT03177603</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <official_title>An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2586881, a purified intravenous (IV) formulation of soluble recombinant human Angiotensin
      Converting Enzyme (rhACE2) is being investigated as a treatment for PAH. This GlaxoSmithKline
      (GSK) study will evaluate the safety, tolerability, pharmacokinetics (PK) and
      pharmacodynamics (PD) of GSK2586881 in subjects with PAH. This open-label, dose-escalation
      study will comprise of 4 separate groups based on the planned dose range, and subjects in
      each group will be administered a single dose of GSK2586881 ranging between 0.2, 0.4, 0.8, or
      1.2 milligram per kilogram (mg/kg) via IV route. Dose escalation will occur after 4 subjects
      have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to
      24 hours post dose has taken place. A maximum of 27 subjects will be included in the study
      and the total duration of the study will be up to a maximum of 59 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">October 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in pulmonary vascular resistance (PVR)</measure>
    <time_frame>Baseline and up to 4 hours</time_frame>
    <description>PVR is the resistance generated by pulmonary circulation. Pulmonary arterial catheters will be placed in subjects and PVR values will be recorded from the right heart catheterization. The catheter will be removed 4 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in cardiac output (CO)</measure>
    <time_frame>Baseline and up to 4 hours</time_frame>
    <description>CO is the amount of blood pumped by the heart per minute. Pulmonary arterial catheters will be placed in subjects and CO values will be recorded from the right heart catheterization. The catheter will be removed 4 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in mean pulmonary artery pressure (mPAP)</measure>
    <time_frame>Baseline and up to 4 hours</time_frame>
    <description>Pulmonary arterial catheters will be placed in subjects and mPAP values will be recorded from the right heart catheterization. The catheter will be removed 4 hours post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Up to 14 days post dose</time_frame>
    <description>An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious adverse events (SAE)</measure>
    <time_frame>Screening and up to 14 days post dose</time_frame>
    <description>Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal clinical laboratory parameters</measure>
    <time_frame>Screening and up to 14 days post dose</time_frame>
    <description>Serum chemistry, hematological and urine analysis parameters will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pulse rate as a safety measure</measure>
    <time_frame>Screening and up to 14 days post dose</time_frame>
    <description>Pulse rate will be measured in a supine position after at least a 5-minute rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of respiratory rate as a safety measure</measure>
    <time_frame>Screening and up to 14 days post dose</time_frame>
    <description>Respiratory rate will be measured in a supine position after at least a 5-minute rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of blood pressure (BP) as a safety measure</measure>
    <time_frame>Screening and up to 14 days post dose</time_frame>
    <description>BP will be measured in a supine position after at least a 5-minute rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram (ECG) findings</measure>
    <time_frame>Screening and up to 14 days post dose</time_frame>
    <description>12-lead ECGs will be obtained at each time point using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and Corrected QT (QTc) intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal pulse oximetry findings</measure>
    <time_frame>Screening and up to 14 days post dose</time_frame>
    <description>Oxygen saturation will be measured by pulse oximetry with each blood pressure assessment after at least a 5-minute rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as a measure of safety assessment</measure>
    <time_frame>Screening and up to 31 days post dose</time_frame>
    <description>Blood samples will be collected at given time points for immunogenicity assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in RAS (Renin-Angiotensin System) peptides</measure>
    <time_frame>Baseline and up to 14 days post dose</time_frame>
    <description>Blood samples will be collected to evaluate change from Baseline in RAS peptides including Angiotensin (Ang) II, Ang (1-7), Ang (1-5), and transpulmonary gradient of AngII/Ang (1-7) ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in N-terminal pro B-type natriuretic peptide (NT pro-BNP)</measure>
    <time_frame>Baseline and up to 24 hours</time_frame>
    <description>Blood samples will be collected at specific time points to evaluate change from Baseline in NT pro-BNP, a biomarker of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in nitric oxide (NO)</measure>
    <time_frame>Baseline and up to 24 hours</time_frame>
    <description>Blood samples will be collected at specific time points to evaluate change from Baseline in NO levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in cardiac troponin-I</measure>
    <time_frame>Baseline and up to 24 hours</time_frame>
    <description>Blood samples will be collected at specific time points to evaluate change from Baseline in cardiac troponin-I, a biomarker of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (tmax) of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve [AUC(0-t)] of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time[AUC(0-inf)] of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The last observed quantifiable concentration (Clast) of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the last quantifiable concentration (tlast) of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma clearance (CL) of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V) of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (t1/2) of GSK2586881</measure>
    <time_frame>Pre-dose, 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose</time_frame>
    <description>Blood samples will be collected at indicated time points and concentrations of GSK2586881 will be determined</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>GSK2586881 - 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of 0.2 mg/kg GSK2586881. Dose escalation up to maximum dose of 1.2mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586881 - 0.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 1.2mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586881 - 0.8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 1.2mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586881 - 1.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single dose of 1.2 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2586881</intervention_name>
    <description>GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 1.2 mg/kg.</description>
    <arm_group_label>GSK2586881 - 0.8 mg/kg</arm_group_label>
    <arm_group_label>GSK2586881 - 0.4 mg/kg</arm_group_label>
    <arm_group_label>GSK2586881 - 1.2 mg/kg</arm_group_label>
    <arm_group_label>GSK2586881 - 0.2 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects must be between 18-75 years of age (inclusive), at the time of signing the
             informed consent.

          -  Documented diagnosis of PAH, defined as mPAP &gt; 25 millimeter of mercury (mmHg) and
             pulmonary wedge pressure (PWP) â‰¤ 15.

          -  Idiopathic PAH (IPAH), Heritable PAH (HPAH), or PAH associated with collagen vascular
             disease, repaired congenital heart disease, or appetite suppressant use.

          -  World Health Organization (WHO) functional class I, II, or III, stable for at least 8
             weeks prior to enrollment.

          -  Hemodynamically stable on background therapy without evidence of right heart failure
             (historic data).

          -  Six minute walk (6MW) distance, as performed at screening or within 6 months prior to
             screening, of &gt; 100 meters (m).

          -  Mean BP of &gt;60 mmHg.

          -  Receiving stable doses of one or more medications that are approved for treatment of
             PAH, including endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and/or
             prostanoids/prostacyclin receptor agonists, for a minimum of 12 consecutive weeks
             before enrollment.

          -  Diuretic dose stable for 8 weeks.

          -  Body weight &lt;90 kg and body mass index (BMI) within the range 18-30 kg per m square
             (kg/m^2).

          -  Male and/or female [following confirmation of negative pregnancy test for Women of
             Childbearing Potential (WOCBP)]. Women who are pregnant or breastfeeding are excluded.

          -  Capable of giving signed informed consent.

        Exclusion Criteria

          -  History of systemic hypotension, defined as systolic BP &lt;90 mmHg and/or diastolic BP
             &lt;50 mmHg.

          -  Hospitalization for PAH associated deterioration in the previous 6 months.

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance, including all prescribed evaluations and follow-up activities.
             Concurrent disease or condition that may interfere with study participation or safety
             include bleeding disorders, arrhythmia, organ transplant, organ failure, current
             neoplasm, poorly controlled diabetes mellitus, and serious neurological disorders.

          -  Complex unrepaired congenital heart disease.

          -  Subjects with Eisenmenger physiology.

          -  Alanine transferase (ALT) &gt;2x upper limit of normal (ULN).

          -  Bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin &lt;35 percent).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Estimated glomerular-filtration-rate (eGFR) &lt;60 milliliter per minute per meter square
             (mL/min/1.73m^2).

          -  QTc &gt;480 millisecond (msec) or QTc &gt; 500 msec in subjects with bundle branch block.

          -  Any bleeding concerns as evidenced by International normalized ratio (INR) &gt;1.5 (in
             subjects not receiving anticoagulation therapy) or platelet count &lt;80,000.

          -  Hemoglobin (Hb) &lt;10 gram per deciliter (g/dL).

          -  Sensitivity to any of the study treatments, or components thereof, or drug or other
             allergy that, in the opinion of the investigator or Medical Monitor, contraindicates
             participation in the study.

          -  Any use of an Angiotensin-converting enzyme (ACE) inhibitor or Angiotensin receptor
             blocker within 14 days prior to dosing. Therapy can be stopped to enable inclusion if
             deemed safe by the subject's treating physician.

          -  Use of any investigational product (IP) or device within 30 days prior to dosing, or
             known requirement for any investigational agent prior to completion of all scheduled
             study assessments.

          -  Positive human immunodeficiency virus (HIV) antibody test.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening.

          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to
             starting study treatment.

          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3
             months prior to first dose of study treatment.

          -  Participation in the study would result in loss of blood or blood products in excess
             of 300mL within 65 days.

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  A known or suspected history of alcohol or drug abuse within the 2 years prior to
             screening.

          -  Unable to refrain from smoking during the in-house treatment period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Dose-escalation</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>GSK2586881</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

